AnaptysBio (NASDAQ:ANAB) Given "Sell (D-)" Rating at Weiss Ratings

Key Points

• AnaptysBio (NASDAQ:ANAB) has been given a "sell (D-)" rating by Weiss Ratings, which has been reiterated recently.
• Multiple brokerages have set varying price targets for AnaptysBio, ranging from $20.00 to $80.00, reflecting mixed sentiment among analysts.
• The company's stock traded up 3.1%, reaching $35.07, with a market capitalization of approximately $981.96 million.

AnaptysBio (NASDAQ:ANAB - Get Free Report)'s stock had its "sell (d-)" rating reiterated by investment analysts at Weiss Ratings in a research report issued on Friday,Weiss Ratings reports.

A number of other brokerages also recently commented on ANAB. Barclays initiated coverage on shares of AnaptysBio in a research note on Monday, October 13th. They set an "overweight" rating and a $78.00 target price on the stock. Wedbush lifted their price target on shares of AnaptysBio from $45.00 to $70.00 and gave the company an "outperform" rating in a research report on Wednesday, October 15th. JPMorgan Chase & Co. lifted their price target on shares of AnaptysBio from $42.00 to $80.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. UBS Group reiterated a "neutral" rating and set a $20.00 price target (up from $18.00) on shares of AnaptysBio in a research report on Tuesday, August 12th. Finally, HC Wainwright lifted their price target on shares of AnaptysBio from $38.00 to $59.00 and gave the company a "buy" rating in a research report on Tuesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $54.78.

AnaptysBio Trading Up 3.1%

ANAB stock traded up $1.07 during trading on Friday, reaching $35.07. 198,201 shares of the stock were exchanged, compared to its average volume of 713,783. The business has a 50 day moving average price of $25.22 and a 200-day moving average price of $23.25. AnaptysBio has a 1 year low of $12.21 and a 1 year high of $35.77. The firm has a market capitalization of $981.96 million, a price-to-earnings ratio of -7.83 and a beta of -0.18.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) EPS for the quarter, topping analysts' consensus estimates of ($1.50) by $0.16. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%. The company had revenue of $22.26 million for the quarter, compared to the consensus estimate of $11.55 million. On average, research analysts anticipate that AnaptysBio will post -6.08 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. US Bancorp DE grew its holdings in shares of AnaptysBio by 126.5% in the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 979 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in AnaptysBio by 175.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 1,377 shares in the last quarter. Osaic Holdings Inc. grew its holdings in AnaptysBio by 11,630.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company's stock worth $52,000 after acquiring an additional 2,326 shares in the last quarter. Brooklyn Investment Group grew its holdings in AnaptysBio by 1,779.9% during the 1st quarter. Brooklyn Investment Group now owns 6,373 shares of the biotechnology company's stock worth $118,000 after acquiring an additional 6,034 shares in the last quarter. Finally, Corton Capital Inc. acquired a new position in AnaptysBio during the 1st quarter worth approximately $199,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.